[go: up one dir, main page]

WO2003068744A1 - Derives de la pyridine ou leurs sels, et inhibiteurs de production de citokine renfermant ces derives - Google Patents

Derives de la pyridine ou leurs sels, et inhibiteurs de production de citokine renfermant ces derives Download PDF

Info

Publication number
WO2003068744A1
WO2003068744A1 PCT/JP2003/001712 JP0301712W WO03068744A1 WO 2003068744 A1 WO2003068744 A1 WO 2003068744A1 JP 0301712 W JP0301712 W JP 0301712W WO 03068744 A1 WO03068744 A1 WO 03068744A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
halogeno
trifluoromethyl
hydrogen
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/001712
Other languages
English (en)
Japanese (ja)
Inventor
Fuminori Kato
Hirohiko Kimura
Shunji Yuki
Kiyoshi Tamai
Mitsuo Sano
Kimie Sakai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ishihara Sangyo Kaisha Ltd
Original Assignee
Ishihara Sangyo Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ishihara Sangyo Kaisha Ltd filed Critical Ishihara Sangyo Kaisha Ltd
Priority to AU2003211427A priority Critical patent/AU2003211427A1/en
Publication of WO2003068744A1 publication Critical patent/WO2003068744A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des inhibiteurs de production de la citokine contenant comme ingrédients actifs, des dérivés de la pyridine représentés par la formule générale (I) ou des sels de ceux-ci, dans laquelle X1 désigne l'hydrogène, un halogéno, nitro, trifluorométhyle, alkyle ou cyano, X2 désigne l'hydrogène, un trifluorométhyle ou un alkyle ; X3 désigne l'hydrogène, un halogéno, trifluorométhyle, alkyle, alcoxycarbonyle, nitro, cyano ou méthylsulfonyle ; X4 désigne un hydrogène, un halogéno, trifluorométhyle, alkyle ou alcoxy ; T désigne O, S, SO, SO2 ou NH; Y désigne un halogéno, un alkyle éventuellement substitué, un alcoxy éventuellement substitué, un nitro, hydroxyle, alkylsulfonylamino, un amino éventuellement alkylé, un alkylcarbonylamino, cycloalkylcarbonylamino, alcoxycarbonylamino, alcoxycarbonylalkylamino, hydroxycarbonylalkylamino, ou O-A-COZ ; et n désigne un nombre entier compris entre 0 et 5.
PCT/JP2003/001712 2002-02-18 2003-02-18 Derives de la pyridine ou leurs sels, et inhibiteurs de production de citokine renfermant ces derives Ceased WO2003068744A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003211427A AU2003211427A1 (en) 2002-02-18 2003-02-18 Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002-040705 2002-02-18
JP2002040705 2002-02-18

Publications (1)

Publication Number Publication Date
WO2003068744A1 true WO2003068744A1 (fr) 2003-08-21

Family

ID=27678312

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/001712 Ceased WO2003068744A1 (fr) 2002-02-18 2003-02-18 Derives de la pyridine ou leurs sels, et inhibiteurs de production de citokine renfermant ces derives

Country Status (2)

Country Link
AU (1) AU2003211427A1 (fr)
WO (1) WO2003068744A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018529A3 (fr) * 2003-08-21 2005-04-21 Astrazeneca Ab Nouveaux composes
US7737135B2 (en) 2004-08-24 2010-06-15 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
CN1845894B (zh) * 2003-08-21 2010-07-07 阿斯利康(瑞典)有限公司 苯氧乙酸衍生物
US8008350B2 (en) 2005-10-06 2011-08-30 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
US8022248B2 (en) 2004-07-08 2011-09-20 Astrazeneca Ab Substituted acids for the treatment of respiratory diseases
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
US8158820B2 (en) 2003-04-07 2012-04-17 Astrazeneca Ab Compounds
US8507544B2 (en) 2007-07-05 2013-08-13 Astrazeneca Ab Bi-aryl amide compounds as CRTh2 receptor modulators
US8524715B2 (en) 2004-11-23 2013-09-03 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
US10899710B2 (en) 2015-08-07 2021-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pyridines and their use in the treatment of cancer
US11028067B2 (en) 2017-02-07 2021-06-08 Oblique Therapeutics Ab Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
US11161815B2 (en) 2017-02-07 2021-11-02 Oblique Therapeutics Ab Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer
US11168069B2 (en) 2017-02-07 2021-11-09 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
US11208384B2 (en) 2017-02-07 2021-12-28 Oblique Therapeutics Ab Sulfinylpyridines and their use in the treatment of cancer
WO2023072795A1 (fr) * 2021-10-27 2023-05-04 Merck Patent Gmbh Dispositif de commutation électronique

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689653A (en) * 1970-07-06 1972-09-05 Schering Corp Compositions and methods for treating inflammation using substituted nicotinic acids
EP0000483A1 (fr) * 1977-07-22 1979-02-07 The Dow Chemical Company Acides trifluorométhyl pyridinyl(oxy/thio)phénoxy propanoiques, les propanols correspondants et leurs dérivés
JPS5455575A (en) * 1977-10-05 1979-05-02 Ishihara Sangyo Kaisha Ltd Phenoxypropionic acid derivative and herbicide containing the same
US4186204A (en) * 1975-06-05 1980-01-29 Eli Lilly And Company Acylamino derivatives
JPS5569566A (en) * 1978-11-17 1980-05-26 Ishihara Sangyo Kaisha Ltd 4-(5-trifluoromethyl-2-pyridylthio)phenoxypropionic acid derivative, and herbicide containing the same
WO1982000400A1 (fr) * 1980-07-30 1982-02-18 Smith L Procede de desherbage selectif sur les mauvaises herbes poussant avec le riz
JPS61126067A (ja) * 1984-11-22 1986-06-13 Ono Pharmaceut Co Ltd ２−アミノフエノ−ル誘導体、その製造方法およびそれらを有効成分として含有する治療剤
JPS62223173A (ja) * 1986-03-25 1987-10-01 Otsuka Pharmaceut Factory Inc ピリジルアミノフエノ−ル誘導体及びその製造方法
JPS6339862A (ja) * 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ピリジルアミノフエノ−ル誘導体
EP0273242A2 (fr) * 1986-12-22 1988-07-06 Bayer Ag 2-Pyri(mi)dylthio-aryléther
WO1995033462A1 (fr) * 1994-06-02 1995-12-14 Smithkline Beecham Corporation Composes anti-inflammatoires
JPH0977740A (ja) * 1995-09-12 1997-03-25 Taisho Pharmaceut Co Ltd ４−アルコキシ−５−アリールチオニトロアニリン化合物
JPH10237028A (ja) * 1996-12-24 1998-09-08 Chugai Pharmaceut Co Ltd Ｎｏｓ阻害作用を有する芳香族アミン誘導体
EP0949242A1 (fr) * 1996-12-24 1999-10-13 Chugai Seiyaku Kabushiki Kaisha Derives d'amine aromatiques ayant une action inhibitrice a l'egard des nos
WO2001040227A1 (fr) * 1999-12-03 2001-06-07 Ono Pharmaceutical Co., Ltd. Derives triazaspiro[5.5]undecane et medicaments contenant ces derives en tant que principe actif
WO2002006276A1 (fr) * 2000-07-13 2002-01-24 Eli Lilly And Company Agonistes adrenergiques beta3
WO2002012191A1 (fr) * 2000-08-08 2002-02-14 Shionogi & Co., Ltd. Derives d'amines cycliques et utilisation
WO2002046161A1 (fr) * 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives de l'acide carboxylique substitues
WO2002051397A1 (fr) * 2000-12-22 2002-07-04 Ishihara Sangyo Kaisha, Ltd. Derives d'aniline ou sels de ceux-ci, ainsi qu'inhibiteurs de production de cytokine contenant ces derives

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689653A (en) * 1970-07-06 1972-09-05 Schering Corp Compositions and methods for treating inflammation using substituted nicotinic acids
US4186204A (en) * 1975-06-05 1980-01-29 Eli Lilly And Company Acylamino derivatives
EP0000483A1 (fr) * 1977-07-22 1979-02-07 The Dow Chemical Company Acides trifluorométhyl pyridinyl(oxy/thio)phénoxy propanoiques, les propanols correspondants et leurs dérivés
JPS5455575A (en) * 1977-10-05 1979-05-02 Ishihara Sangyo Kaisha Ltd Phenoxypropionic acid derivative and herbicide containing the same
JPS5569566A (en) * 1978-11-17 1980-05-26 Ishihara Sangyo Kaisha Ltd 4-(5-trifluoromethyl-2-pyridylthio)phenoxypropionic acid derivative, and herbicide containing the same
WO1982000400A1 (fr) * 1980-07-30 1982-02-18 Smith L Procede de desherbage selectif sur les mauvaises herbes poussant avec le riz
JPS61126067A (ja) * 1984-11-22 1986-06-13 Ono Pharmaceut Co Ltd ２−アミノフエノ−ル誘導体、その製造方法およびそれらを有効成分として含有する治療剤
JPS62223173A (ja) * 1986-03-25 1987-10-01 Otsuka Pharmaceut Factory Inc ピリジルアミノフエノ−ル誘導体及びその製造方法
JPS6339862A (ja) * 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ピリジルアミノフエノ−ル誘導体
EP0273242A2 (fr) * 1986-12-22 1988-07-06 Bayer Ag 2-Pyri(mi)dylthio-aryléther
WO1995033462A1 (fr) * 1994-06-02 1995-12-14 Smithkline Beecham Corporation Composes anti-inflammatoires
JPH0977740A (ja) * 1995-09-12 1997-03-25 Taisho Pharmaceut Co Ltd ４−アルコキシ−５−アリールチオニトロアニリン化合物
JPH10237028A (ja) * 1996-12-24 1998-09-08 Chugai Pharmaceut Co Ltd Ｎｏｓ阻害作用を有する芳香族アミン誘導体
EP0949242A1 (fr) * 1996-12-24 1999-10-13 Chugai Seiyaku Kabushiki Kaisha Derives d'amine aromatiques ayant une action inhibitrice a l'egard des nos
WO2001040227A1 (fr) * 1999-12-03 2001-06-07 Ono Pharmaceutical Co., Ltd. Derives triazaspiro[5.5]undecane et medicaments contenant ces derives en tant que principe actif
WO2002006276A1 (fr) * 2000-07-13 2002-01-24 Eli Lilly And Company Agonistes adrenergiques beta3
WO2002012191A1 (fr) * 2000-08-08 2002-02-14 Shionogi & Co., Ltd. Derives d'amines cycliques et utilisation
WO2002046161A1 (fr) * 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives de l'acide carboxylique substitues
WO2002051397A1 (fr) * 2000-12-22 2002-07-04 Ishihara Sangyo Kaisha, Ltd. Derives d'aniline ou sels de ceux-ci, ainsi qu'inhibiteurs de production de cytokine contenant ces derives

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158820B2 (en) 2003-04-07 2012-04-17 Astrazeneca Ab Compounds
US8394986B2 (en) 2003-08-21 2013-03-12 Astrazeneca Ab Phenoxiacetic acid derivatives
AU2004266485B2 (en) * 2003-08-21 2008-05-15 Astrazeneca Ab Phenoxiacetic acid derivatives
CN1845894B (zh) * 2003-08-21 2010-07-07 阿斯利康(瑞典)有限公司 苯氧乙酸衍生物
US8003703B2 (en) 2003-08-21 2011-08-23 Astrazeneca Ab Phenoxiacetic acid derivatives
WO2005018529A3 (fr) * 2003-08-21 2005-04-21 Astrazeneca Ab Nouveaux composes
US8022248B2 (en) 2004-07-08 2011-09-20 Astrazeneca Ab Substituted acids for the treatment of respiratory diseases
US7737135B2 (en) 2004-08-24 2010-06-15 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
US8722741B2 (en) 2004-08-24 2014-05-13 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
US8163727B2 (en) 2004-08-24 2012-04-24 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
US8524715B2 (en) 2004-11-23 2013-09-03 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
US8008350B2 (en) 2005-10-06 2011-08-30 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
US8415394B2 (en) 2005-10-06 2013-04-09 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
US8349897B2 (en) 2005-10-06 2013-01-08 Astrazeneca Ab Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
US8507544B2 (en) 2007-07-05 2013-08-13 Astrazeneca Ab Bi-aryl amide compounds as CRTh2 receptor modulators
US10899710B2 (en) 2015-08-07 2021-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pyridines and their use in the treatment of cancer
US11028067B2 (en) 2017-02-07 2021-06-08 Oblique Therapeutics Ab Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
US11161815B2 (en) 2017-02-07 2021-11-02 Oblique Therapeutics Ab Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer
US11168069B2 (en) 2017-02-07 2021-11-09 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
US11208384B2 (en) 2017-02-07 2021-12-28 Oblique Therapeutics Ab Sulfinylpyridines and their use in the treatment of cancer
WO2023072795A1 (fr) * 2021-10-27 2023-05-04 Merck Patent Gmbh Dispositif de commutation électronique

Also Published As

Publication number Publication date
AU2003211427A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
WO2003068744A1 (fr) Derives de la pyridine ou leurs sels, et inhibiteurs de production de citokine renfermant ces derives
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
SE0202463D0 (sv) Novel compounds
WO2005074643A3 (fr) Composes chimiques
AU2003226572A1 (en) Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
YU69902A (sh) Novi derivati piperazina
AU2003215753A1 (en) Imidazopyridine derivatives as kinase inhibitors
WO2004031401A3 (fr) Nouveaux inhibiteurs de tyrosine kinases
DK1864975T3 (da) Nikotinamid-derivater anvendelige som P38-inhibitorer
EP1344525A4 (fr) Derives d'aniline ou sels de ceux-ci, ainsi qu'inhibiteurs de production de cytokine contenant ces derives
IL156873A0 (en) Pharmaceutically active piperidine derivatives
EP1340755A4 (fr) Agents de traitement des infections a helicobacter
AU2003246100A1 (en) Amide derivative
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
WO2003042185A1 (fr) Inhibiteurs de la xanthine oxydase
DK0566199T3 (da) 1,2,4-oxadiazolyl-phenoxyalkylisoxazoler og deres anvendelse som antivirale midler
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
GB0308201D0 (en) Novel compounds
NO20013409L (no) Anvendelse av pyrimidin-derivater for forhindring og behandling av cerebral ischemi
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
EP1813270A4 (fr) Inhibiteurs des proteines de la famille hsp90
SE9803773D0 (sv) Compounds
WO2006110173A3 (fr) Nouveaux composes
ATE332695T1 (de) Pyrimidin-derivate als selektive inhibitoren von cox-2
ATE373636T1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP